All In Biotech

Drug Trial Radar · NCT06431763

A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.

A Randomized, Multicenter, Open-label Trial Comparing the Effectiveness of Inclisiran to Bempedoic Acid on LDL Cholesterol (LDL-C) Lowering in Participants With Atherosclerotic Cardiovascular Disease (VICTORION-CHALLENGE)

Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 402 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

402

Actual

Start

Jun 21, 2024

Primary completion

Dec 1, 2025

Study completion Jan 2, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase IV, open-label, randomized study designed to evaluate the efficacy of Inclisiran vs. bempedoic acid (BPA) in 400 adult subjects (≥ 18 years) at very high and high risk for cardiovascular events as defined by the cardiovascular risk categories in the 2019 ESC/EAS guidelines for the management of dyslipidemias (Mach et al 2020) and elevated levels of LDL-C (≥ 70 mg/dL) despite being on a maximally tolerated high-intensity (HI) statin dose (+/- Ezetimibe). Currently, BPA is recommended ahead of injectables by German HTA body (GBA). A head-to-head trial is proposed to provide robust scientific data on the superiority of Inclisiran vs. BPA and to support the early use of Inclisiran.

Conditions

  • Hypercholesterolemia

Interventions

  • Inclisiran sodiumDrug

    300 mg s.c. administered at day 1 and day 90

  • BPADrug

    180 mg daily per oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in LDL-C levelsTime frame: Baseline, Day 150

Locations

55 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Aachen, Germany

  • Novartis Investigative Site

    Bad Homburg, Germany

  • Novartis Investigative Site

    Bad Krozingen, Germany

  • Novartis Investigative Site

    Bad Oeynhausen, Germany

  • Novartis Investigative Site

    Bamberg, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Bochum, Germany

  • Novartis Investigative Site

    Bochum, Germany

  • Novartis Investigative Site

    Bremen, Germany

  • Novartis Investigative Site

    Dessau, Germany

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Erfurt, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Falkensee, Germany

  • Novartis Investigative Site

    Gladbeck, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Hoyerswerda, Germany

  • Novartis Investigative Site

    Kassel, Germany

  • Novartis Investigative Site

    Kiel, Germany

  • Novartis Investigative Site

    Ludwigshafen, Germany

  • Novartis Investigative Site

    Magdeburg, Germany

  • Novartis Investigative Site

    Markkleeberg, Germany

  • Novartis Investigative Site

    Meissen, Germany

  • Novartis Investigative Site

    Münster, Germany

  • Novartis Investigative Site

    Papenburg, Germany

  • Novartis Investigative Site

    Pirna, Germany

  • Novartis Investigative Site

    Potsdam, Germany

  • Novartis Investigative Site

    Rüdersdorf, Germany

  • Novartis Investigative Site

    Ulm, Germany

  • Novartis Investigative Site

    Völklingen, Germany

  • Novartis Investigative Site

    Mannheim, Baden-Wurttemberg, Germany

  • Novartis Investigative Site

    Stuttgart, Baden-Wurttemberg, Germany

  • Novartis Investigative Site

    Lichtenfels, Bavaria, Germany

  • Novartis Investigative Site

    Muehldorf Am Inn, Bavaria, Germany

  • Novartis Investigative Site

    Regensburg, Bavaria, Germany

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.